Please provide your email address to receive an email when new articles are posted on . "There was no increase in response rate, which was their primary endpoint, despite being a phase 3 study with ...
Please provide your email address to receive an email when new articles are posted on . The phase 3 randomized study, presented at ASCO Annual Meeting, evaluated the overall response rate of ...
The combination treatment specifically targets KRAS-mutated metastatic colorectal cancer (CRC) to improve progression-free survival. The approval was based on results from CodeBreaK 300, a phase 3, ...
We randomly assigned 463 patients with 1% or more EGFR tumor cell membrane staining, measurable disease, and radiologic documentation of disease progression during or within 6 months of most recent ...
CHICAGO -- For metastatic colorectal cancer patients with RAS and BRAF wild-type disease, intensifying the upfront chemotherapy backbone in combination with the anti-EGFR antibody panitumumab ...
Use of circulating endothelial cells to predict response to FOLFOX4 plus bevacizumab in metastatic colorectal cancer. Background: While FOLFOX or FOLFIRI with bevacizumab are the standard first-line ...
On Thursday, Sept. 16, 2021, at 8:30 a.m. ET, David M. Reese, M.D., executive vice president of Research and Development at Amgen, along with other members of Amgen's management team, will discuss ...
The US Food and Drug Administration (FDA) has approved sotorasib (Lumakras, Amgen Inc.) with panitumumab (Vectibix, Amgen Inc.) for the treatment of certain adult patients with metastatic colorectal ...
Rechallenge with an EGFR inhibitor in addition to standard therapy led to significantly better progression-free survival (PFS) in third-line metastatic colorectal cancer (mCRC) versus standard therapy ...
ORLANDO, Fla., (May 17, 2005) – Amgen Inc. (Nasdaq: AMGN), the world's largest biotechnology company, and Abgenix, Inc. (Nasdaq: ABGX), a leading antibody development company, today announced updated ...
THOUSAND OAKS, Calif., March 18, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today issued the following statement: Amgen has received notice that the Committee for Medicinal Products for Human Use (CHMP ...
A suspicion from retrospective data has now been confirmed by a prospective clinical trial: adding panitumumab (Vectibix) to standard chemotherapy in left-sided RAS wild-type metastatic colorectal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results